View Older Stories View More Recent Stories
-
Novo Nordisk (NVO) call put ratio 1.9 calls to 1 put into quarter results
-
After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina
-
Hims & Hers in talks with Novo Nordisk to offer Wegovy treatments
-
Metsera responds to Pfizer litigation amid competing acquisition bids
-
Pfizer files second lawsuit against Novo Nordisk over Metsera acquisition
-
Metsera responds to Pfizer litigation, will address claims in court
-
Pfizer sues Metsera directors and Novo Nordisk over merger breach
-
Pfizer gets early FTC clearance for Metsera acquisition
-
Pfizer mulls suing Metsera, Novo Nordisk over topping bid - Semafor
-
Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ
-
Novo Nodrisk stock dips on aggressive odder to buy Metsera, 'reckless' says Pfizer
-
Novo Nordisk makes $9 billion bid for Metsera amid Pfizer deal
-
Pfizer calls Novo Nordisk's Metsera bid reckless and illegal
-
Novo Nordisk submits $6.5 billion offer for Metsera
-
Jefferies Assumes Novo Nordisk (NOVOB:DC) (NVO) at Underperform
-
Novo Nordisk (NVO) to hold EGM, Chair Helge Lund will not stand for reelection
-
Novo Nordisk calls extraordinary meeting to elect new board members
-
Novo Nordisk (NVO) call put ratio 1.2 calls to 1 put
-
After-hours movers: CSX Corp, Interactive Brokers, Novo Nordisk, Lilly
-
Eli Lilly Shares Fall 2.7%, Novo Drops 2.8%; Trump: Ozempic, Fatloss Drug Prices To Come Down 'pretty Fast'
-
Novo Nordisk (NVO): FDA approves Wegovy's supplemental NDA as amended for labeling with minor editorial revisions
-
Novo Nordisk (NVO) to announce layoffs in the U.S. - Reuters
-
Novo Nordisk (NVO) PT Raised to $55 at BMO Capital
-
Novo Nordisk to acquire Akero Therapeutics for up to $5.2 billion
-
Novo Nordisk (NVO) call put ratio 3.8 calls to 1 put with a focus on a spreader of December 60 and 85 calls
-
Goldman Sachs Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip
-
Morgan Stanley Downgrades Novo Nordisk (NVO) to Underweight
-
Morgan Stanley Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Underweight
-
EU will still have 15% pharma tariff, not 100% - Bloomberg
-
Novo Nordisk: Diabetes and obesity GLP-1 portfolio still attractive says Bernstein
-
UBS slashes global GLP-1 sales estimate for 2030 on softer outlook
-
Walmart (WMT) Adds Home Delivery for Ozempic, Other Refrigerated Drugs - Bloomberg
-
Trump: tariffs will get countries to agree to drug pricing plan
-
Novo Nordisk Cuts U.S. Obesity Education Team As Layoffs Begin, Say Sources, Online Posts - Reuters
-
BMO Capital on Novo Nordisk (NVO): 'still give the competitive edge to Lilly following this week'
-
UBS Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk (NVO) call put ratio 3.2 calls to 1 put into share price up before the bell
-
Novo Nordisk's oral weight loss pill shows 16.6% weight loss in trial
-
Berenberg Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Buy
-
Novo Nordisk (NVO) issued warning letter by FDA over misleading Wegovy promotion
-
FDA issues warning letter to Novo Nordisk over misleading drug promotion
-
How are GLP-1 drugs changing U.S. grocery behavior?
-
Novo Nordisk's Wegovy may quiet thoughts about food, study shows; shares up
-
Rothschild Redburn Upgrades Novo Nordisk (NVO) to Buy
-
Novo Nordisk receives EU approval for cardiovascular benefits of oral semaglutide
-
Novo Nordisk (NVO) stock: Barclays breaks down key investor questions and debates
-
BMO Capital on Novo Nordisk (NVO): 'New CEO Doustdar Implements Massive Restructuring'
-
Novo Nordisk to cut 9,000 jobs in major restructuring
-
Bernstein SocGen Group Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Outperform

